Literature DB >> 25824734

The spectrum of genetic mutations in breast cancer.

Asfandyar Sheikh1, Syed Ather Hussain, Quratulain Ghori, Nida Naeem, Abul Fazil, Smith Giri, Brijesh Sathian, Prajeena Mainali, Dalal M Al Tamimi.   

Abstract

Breast cancer is the most common malignancy in women around the world. About one in 12 women in the West develop breast cancer at some point in life. It is estimated that 5%-10% of all breast cancer cases in women are linked to hereditary susceptibility due to mutations in autosomal dominant genes. The two key players associated with high breast cancer risk are mutations in BRCA 1 and BRCA 2. Another highly important mutation can occur in TP53 resulting in a triple negative breast cancer. However, the great majority of breast cancer cases are not related to a mutated gene of high penetrance, but to genes of low penetrance such as CHEK2, CDH1, NBS1, RAD50, BRIP1 and PALB2, which are frequently mutated in the general population. In this review, we discuss the entire spectrum of mutations which are associated with breast cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25824734     DOI: 10.7314/apjcp.2015.16.6.2177

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  18 in total

1.  A novel loss-of-function heterozygous BRCA2 c.8946_8947delAG mutation found in a Chinese woman with family history of breast cancer.

Authors:  Jing Ma; Jichun Yang; Wenjing Jian; Xianming Wang; Deyong Xiao; Wenjun Xia; Likuan Xiong; Duan Ma
Journal:  J Cancer Res Clin Oncol       Date:  2017-01-05       Impact factor: 4.553

Review 2.  Pancreatic Cancer and Therapy: Role and Regulation of Cancer Stem Cells.

Authors:  Susmita Barman; Iram Fatima; Amar B Singh; Punita Dhawan
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

3.  Sputum Detection of Predisposing Genetic Mutations in Women with Pulmonary Nontuberculous Mycobacterial Disease.

Authors:  Julie V Philley; Kate L Hertweck; Anbarasu Kannan; Barbara A Brown-Elliott; Richard J Wallace; Anna Kurdowska; Harrison Ndetan; Karan P Singh; Edmund J Miller; David E Griffith; Santanu Dasgupta
Journal:  Sci Rep       Date:  2018-07-27       Impact factor: 4.379

4.  Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.

Authors:  Shanshan Yu; Chuan Hu; Lixiao Liu; Luya Cai; Xuedan Du; Qiongjie Yu; Fan Lin; Jinduo Zhao; Ye Zhao; Cheng Zhang; Xuan Liu; Wenfeng Li
Journal:  J Transl Med       Date:  2020-07-28       Impact factor: 5.531

5.  Role of Four ABC Transporter Genes in Pharmacogenetic Susceptibility to Breast Cancer in Jordanian Patients.

Authors:  Laith N Al-Eitan; Doaa M Rababa'h; Mansour A Alghamdi; Rame H Khasawneh
Journal:  J Oncol       Date:  2019-07-17       Impact factor: 4.375

6.  Prognostic significance of mutant-allele tumor heterogeneity in uterine corpus endometrial carcinoma.

Authors:  Yufang Hou; Tiegang Li; Wenqiang Gan; Silin Lv; Zifan Zeng; Zheng Yan; Weiqi Wang; Min Yang
Journal:  Ann Transl Med       Date:  2020-03

7.  A Step Forward in Breast Cancer Research: From a Natural-Like Experimental Model to a Preliminary Photothermal Approach.

Authors:  Eduardo Costa; Tânia Ferreira-Gonçalves; Miguel Cardoso; João M P Coelho; Maria Manuela Gaspar; Pedro Faísca; Lia Ascensão; António S Cabrita; Catarina Pinto Reis; Isabel V Figueiredo
Journal:  Int J Mol Sci       Date:  2020-12-18       Impact factor: 5.923

8.  SOX7 co-regulates Wnt/β-catenin signaling with Axin-2: both expressed at low levels in breast cancer.

Authors:  Huidi Liu; Emilio Mastriani; Zi-Qiao Yan; Si-Yuan Yin; Zheng Zeng; Hong Wang; Qing-Hai Li; Hong-Yu Liu; Xiaoyu Wang; Hong-Xia Bao; Yu-Jie Zhou; Jun-Jie Kou; Dongsheng Li; Ting Li; Jianrui Liu; Yongfang Liu; Lin Yin; Li Qiu; Liling Gong; Shu-Lin Liu
Journal:  Sci Rep       Date:  2016-05-18       Impact factor: 4.379

9.  Systematic analysis of lysine acetylome and succinylome reveals the correlation between modification of H2A.X complexes and DNA damage response in breast cancer.

Authors:  Xiuli Gao; Hongguang Bao; Likun Liu; Wenbin Zhu; Liping Zhang; Liling Yue
Journal:  Oncol Rep       Date:  2020-03-19       Impact factor: 3.906

Review 10.  Immunotherapy: A Challenge of Breast Cancer Treatment.

Authors:  Marilina García-Aranda; Maximino Redondo
Journal:  Cancers (Basel)       Date:  2019-11-20       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.